PCD logo

Opioid-Related Hospitalization and Its Association With Chronic Diseases: Findings From the National Inpatient Sample, 2011–2015

Janani Rajbhandari-Thapa, PhD1; Donglan Zhang, PhD1; Heather M Padilla, PhD2; Sae Rom Chung, MS3 (View author affiliations)

Suggested citation for this article: Rajbhandari-Thapa J, Zhang D, Padilla HM, Chung SR. Opioid-Related Hospitalization and Its Association With Chronic Diseases: Findings From the National Inpatient Sample, 2011–2015. Prev Chronic Dis 2019;16:190169. DOI: http://dx.doi.org/10.5888/pcd16.190169.

PEER REVIEWED

Summary

What is already known on this topic?

Patients who take addictive pain relievers often have chronic conditions.

What is added by this report?

From 2011 to 2015, more than 90% of US opioid-related hospitalizations were among patients with 2 or more chronic diseases. The trend in opioid-related hospitalization among patients with multiple chronic diseases is increasing and noteworthy.

What are the implications for public health practice?

Multiple chronic diseases are associated with opioid-related hospitalizations, indicating that prevention of opioid-related abuse and overdose among patients with multiple chronic conditions requires alternatives to opioid prescription, when possible.

Abstract

Chronic disease and opioid-related hospitalizations in the United States are increasing. We analyzed nationally representative data on patients aged 18 years or older from the 2011–2015 National Inpatient Sample to assess the association between opioid-related hospitalization and chronic diseases. We found that most patients with opioid-related hospitalization were white, aged 35–54 years, in urban hospitals, and had 2 or more comorbid conditions. Patients with 2 or more chronic conditions accounted for more than 90% of opioid-related hospitalizations in all years. The results suggest a need for targeted interventions to prevent opioid misuse in patients with multiple chronic conditions.

Top

Objective

Patients with chronic conditions such as cancer, stroke, asthma, and obesity often experience chronic pain and have a higher likelihood of receiving one or more opioid prescriptions (1). In this study, we examined whether the prevalence of opioid-related hospitalization was associated with chronic diseases among inpatients. This study is the first to examine the prevalence of opioid-related hospitalization and chronic disease among patients admitted to community hospitals. Opioid-related inpatient stays (2) have increased, mainly due to opioid abuse, addiction, poisoning, and dependence, resulting from misuse of opioid pain relievers that are often originally prescribed (3) to treat chronic pain.

Top

Methods

In this cross-sectional study, we analyzed data on patients aged 18 years or older from the National Inpatient Sample (NIS) from January 1, 2011, to September 30, 2015. Claims occurring from October through December of 2015 were not included because of the transition from the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) to the 10th revision (ICD-10-CM) coding system on October 1, 2015. We included arthritis, spinal disease, asthma, liver disease, stroke, cancer, and obesity because these diseases are most likely to be prescribed opioids in the internal and family medicine specialties. Family medicine (21.8%) and internal medicine (17.6%) reportedly write the most opioid prescriptions, followed by physical medicine/rehabilitation, anesthesiology/pain, hematology/oncology, and neurology (4–6). Relationships between asthma and opioid abuse and dependence (7) and between chronic liver disease and opioid use (8) have been established, as has a relationship between stroke and opioid abuse among young stroke patients (9). Cancer patients rely on opioid medications for relief from cancer pain (10). Obesity was included because of its significant association with chronic pain (11). Using the NIS sample, we identified 3,239,136 opioid-related hospitalization cases for from January 1, 2011, to September 30, 2015.

We combined opioid dependence and unspecified use, adverse effects of opioids, opioid abuse, and opioid poisoning to create a single variable, opioid-related hospitalization (specific ICD-9-CM codes are available in Appendices A and B. The data were weighted by using sampling weights provided by the NIS Healthcare Cost and Utilization Project (12). For creating national estimates for the prevalence of opioid-related hospitalizations and all analyses, we implemented Stata’s trend weight (TRENDWT) for 2011 and discharge weight (DISCWT) from 2012 through 2015 (StataCorp LLC). Because of the redesign of NIS data in 2012, we used TRENDWT for 2011, which allowed the national estimates for trend analysis in 2011 to be consistent with data from 2012–2015. To use trend weight, we merged the trend weight file (www.hcup-us.ahrq.gov/db/nation/nis/trendwghts.jsp) into the original NIS 2011 data. We analyzed the trends in opioid-related hospitalizations by type of chronic disease for 2011–2015 and used the Pearson χ2 test to test for significance. Significance was set at P < .05.

Top

Results

The highest total number of opioid-related hospitalization cases was in 2014 (n = 704,670) (Table 1). From 2011 to 2015, the highest prevalence of opioid-related hospitalization was among patients aged 35–54 years (5-year average, 37%), followed by those aged 18–34 years. The percentages of men and women with opioid-related hospitalizations were approximately equal. The highest prevalence of opioid-related hospitalization was among white patients (5-year average, 72%), and the second-highest was among black patients (5-year average, 15%). The prevalence was higher in urban hospitals (5-year prevalence range, 58%–64%) than in rural hospitals (5-year prevalence range, 36%–42%). The prevalence was also higher among patients who used Medicaid and Medicare than among those who did not. The prevalence of opioid-related hospitalization was highest (94%) among patients with 2 or more comorbid conditions. In 2014 and 2015, as many as 95% of the patients hospitalized for opioid-related causes had 2 or more comorbid conditions.

The prevalence of opioid-related hospitalizations significantly increased among patients with cancer, stroke, obesity, asthma, liver disease, and arthritis across all years (Table 2). The most prevalent chronic disease significantly associated with opioid-related hospitalization was asthma, followed by obesity and liver disease. There was a significant association between opioid-related hospitalization and cancer, stroke, obesity, asthma, and liver disease every year of the study period, with the exception of cancer in 2013 and obesity in 2015. The association between arthritis and opioid-related hospitalizations was significant only in 2014 and 2015, and the association between spinal diseases and opioid-related hospitalizations was significant only in 2012 and 2015.

Top

Discussion

We found that more than 90% of opioid-related hospitalizations were among patients with 2 or more chronic diseases and that the trend in opioid-related hospitalization among patients with chronic diseases is increasing. This finding is salient given that 1 in 4 US adults are living with 2 or more chronic diseases (13). Both the opioid crisis and rising rates of chronic disease have been described as epidemics; however, they are currently being treated separately. The US Department of Health and Human Services’ 5-point strategy to combat the opioid crisis focuses on the treatment of addiction, which is important for addressing the epidemic in the short term (14). A population-level approach to preventing and treating chronic diseases is also needed. Health services must address the 2 issues — opioid misuse and management of chronic disease — simultaneously.

Using alternative approaches to pain management is one public health strategy for addressing the opioid crisis (15) and is consistent with the Centers for Disease Control and Prevention’s (CDC’s) Guideline for Prescribing Opioids for Chronic Pain (16). Based on our findings, this approach may be particularly important in patients with multiple chronic diseases. Consistent with the CDC guideline, nonpharmacologic treatment including exercise therapy and cognitive behavioral therapy, as well as multimodal therapies combining exercise therapy with psychologically based approaches, should be used to decrease pain and improve functional ability (16). When opioids are used for pain management, patients with multiple chronic diseases may require close monitoring and additional education on risks of misuse.

This study has several limitations. Because we analyzed data from 2011 to 2015, our findings are not generalizable to more recent years. Our analysis was cross-sectional and examined the associations between opioid-related hospitalization and chronic diseases without controlling for covariates, which prevents us from drawing causal conclusions about the direction of the observed relationship. Furthermore, the nature of the data did not allow us to explore why the associations were not significant in some years. Opioid prescriptions for patients with arthritis have increased in recent years, so that could be an explanation for the strong correlation we found (17). Finally, we studied a small number of chronic diseases and did not assess any diseases related to mental health.

Despite these limitations, our findings show an increasing trend in opioid-related hospitalization among patients with chronic diseases and a high prevalence of opioid-related hospitalization among patients with multiple chronic conditions. The observed association warrants further research to determine causal inference. Results from this study can help clinicians develop strategies to prevent opioid misuse in patients with multiple chronic conditions and inform strategies for addressing both the opioid epidemic and rising rates of chronic disease.

Top

Acknowledgments

Funding sources: University of Georgia Office of Vice President for Research and College of Public Health to purchase data. No copyrighted material, surveys, instruments, or tools were used to produce this article.

Top

Author Information

Corresponding Author: Janani Rajbhandari-Thapa, PhD, Assistant Professor, Department of Health Policy and Management, College of Public Health, University of Georgia, Athens, GA 30602. Telephone: 706-713-2700. Email: jrthapa@uga.edu.

Author Affiliations: 1Department of Health Policy and Management, College of Public Health, University of Georgia, Athens, Georgia. 2Department of Health Promotion and Behavior, College of Public Health, University of Georgia, Athens, Georgia. 3Department of Financial Planning, Housing, and Consumer Economics, College of Family and Consumer Sciences, University of Georgia, Athens, Georgia.

Top

References

  1. Volkow ND, McLellan AT. Opioid abuse in chronic pain — misconceptions and mitigation strategies. N Engl J Med 2016;374(13):1253–63. CrossRef PubMed
  2. National Institute on Drug Abuse. Opioids. https://www.drugabuse.gov/drugs-abuse/opioids. Accessed January 7, 2019.
  3. Compton WM, Boyle M, Wargo E. Prescription opioid abuse: problems and responses. Prev Med 2015;80:5–9. CrossRef PubMed
  4. Volkow ND, McLellan TA, Cotto JH, Karithanom M, Weiss SR. Characteristics of opioid prescriptions in 2009. JAMA 2011;305(13):1299–301. CrossRef PubMed
  5. Levy B, Paulozzi L, Mack KA, Jones CM. Trends in opioid analgesic-prescribing rates by specialty, US, 2007–2012. Am J Prev Med 2015;49(3):409–13. CrossRef PubMed
  6. Weiner SG, Baker O, Rodgers AF, Garner C, Nelson LS, Kreiner PW, et al. Opioid prescriptions by specialty in Ohio, 2010–2014. Pain Med 2018;19(5):978–89. CrossRef PubMed
  7. Ruigómez A, Rodríguez LAG, Wallander M-A, Johansson S, Jones R. Chest pain in general practice: incidence, comorbidity and mortality. Fam Pract 2006;23(2):167–74. CrossRef PubMed
  8. Rogal SS, Winger D, Bielefeldt K, Szigethy E. Pain and opioid use in chronic liver disease. Dig Dis Sci 2013;58(10):2976–85. CrossRef PubMed
  9. Indupuru HK, Fraher C, Bambhroliya AB, Meyer E, Meeks JR, Vahidy F. Abstract TMP51: Nationwide estimates of opioid abuse in young stroke patients. Philadelphia (PA): Lippincott, Williams, and Wilkins; 2018.
  10. Bennett M, Paice JA, Wallace M. Pain and opioids in cancer care: benefits,risks, and alternatives. Am Soc Clin Oncol Educ Book 2017;37:705–13. CrossRef PubMed
  11. Okifuji A, Hare BD. The association between chronic pain and obesity. J Pain Res 2015;8:399–408. CrossRef PubMed
  12. US HCUP NIS Database Documentation. Healthcare Cost and Utilization Project (HCUP): NIS Database Documentation. Rockville (MD): Agency for Healthcare Research and Quality. https://www.hcup-us.ahrq.gov/db/nation/nis/nisdbdocumentation.jsp. Accessed October 22, 2019.
  13. Ward BW, Schiller JS. Prevalence of multiple chronic conditions among US adults: estimates from the National Health Interview Survey, 2010. Prev Chronic Dis 2013;10:120203. CrossRef PubMed
  14. US Department of Health and Human Services. Opioids: the prescription drug and heroin overdose epidemic. https://www.hhs.gov/opioids/. Accessed January 9, 2019.
  15. Saloner B, McGinty EE, Beletsky L, Bluthenthal R, Beyrer C, Botticelli M, et al. A public health strategy for the opioid crisis. Public Health Rep 2018;133(1S):24S–34S. CrossRef PubMed
  16. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain — United States, 2016. MMWR Recomm Rep 2016;65(No. RR-1):1–49. CrossRef PubMed
  17. Zamora-Legoff JA, Achenbach SJ, Crowson CS, Krause ML, Davis JM 3d, Matteson EL. Opioid use in patients with rheumatoid arthritis 2005–2014: a population-based comparative study. Clin Rheumatol 2016;35(5):1137–44. CrossRef PubMed

Top

Tables

Return to your place in the text

Table 1. Prevalence of Opioid-Related Hospitalizations Among Adults Aged 18 or Older, National Inpatient Sample, 2011–2015a
Characteristic Yearb
2011 (n = 639,586) 2012 (n = 655,520) 2013 (n = 664,480) 2014 (n = 704,670) 2015 (n = 574,880)
Age, y
18–34 29.35 30.30 30.37 29.98 29.22
35–54 39.51 38.23 37.07 36.29 35.97
55–64 15.86 16.50 17.06 17.60 18.37
≥65 15.29 14.97 15.50 16.12 16.44
Sex
Male 49.73 49.34 49.02 49.15 49.63
Female 50.27 50.66 50.98 50.85 50.37
Race/ethnicity
White 70.76 71.26 72.67 73.16 72.99
Black 16.30 15.36 14.22 14.12 14.44
Hispanic 8.33 8.70 8.79 8.30 8.38
Asian 0.69 0.78 0.75 0.84 0.88
Native American 0.65 0.70 0.65 0.74 0.77
Other 3.27 3.20 2.84 2.84 2.59
No. of comorbidities
None 0.69 0.57 0.54 0.39 0.40
One 5.39 5.41 4.97 4.49 4.23
Two or more 93.91 94.02 94.48 95.12 95.37
Rural/urban status
Rural 35.59 40.81 42.04 41.57 41.71
Urban 64.41 59.19 57.96 58.43 58.29
Payer
Medicaid 30.74 31.61 31.29 37.66 39.30
Medicare 30.20 30.62 31.56 31.85 31.53
Private 21.22 21.06 20.72 19.62 19.61
Self-pay 13.35 12.19 12.02 7.80 6.45
Other 4.49 4.52 4.41 3.08 3.11

a Data are percentages, per 100,000 hospitalizations; sampling weight adjusted in all statistics.
b Values for n indicate the total number of opioid-related hospitalizations for the year.

Return to your place in the text

Table 2. Prevalence of Opioid-Related Hospitalizations Among Adults Aged 18 or Older, by Chronic Disease, National Inpatient Sample, 2011–2015a
Chronic Disease Year P Valueb
2011 2012 2013 2014 2015
Cancer 1.11c 1.16c 1.32 1.40c 1.58c <.001
Stroke 0.90c 0.93c 1.04c 1.04c 1.07c <.001
Obesity 8.18c 8.92c 9.67c 10.21c 10.80 <.001
Asthma 10.77c 11.18c 10.93c 11.49c 11.91c <.001
Liver Disease 4.76c 4.77c 5.12c 5.21c 5.35c <.001
Spinal Disease 0.83 0.75d 0.77 0.77 0.80c .09
Arthritis 1.65 1.67 1.73 1.83d 1.96c <.001

a Data are percentages, per 100,000 hospitalizations; sampling weight adjusted in all statistics.
b Trend analysis was calculated by using χ2 test.
c P < .001. P values calculated by using test.
d P < .05. P values calculated by using test.

Top

Top

 

Return to your place in the text

Appendix A. International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) Diagnosis Codes Used to Identify Opioid-Related Hospitalization

International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) Diagnosis Codes Used to Identify Opioid-Related Hospitalization
Hospitalization Type ICD-9-CM Code
Opioid dependence and unspecified use 304.00, 304.01, 304.07, 304.71
Adverse effects of opioids E935.1, E935.2, E940.1
Opioid abuse 305.50, 305.51, 305.52
Opioid poisoning 965.00, 965.01, 965.02, 965.09, 970.1, E850.0, E850.1, E850.2

Top

 

Return to your place in the text

Appendix B. International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) Diagnosis Codes Used to Identify Comorbidities

International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) Diagnosis Codes Used to Identify Comorbidities
Comorbidity ICD-9-CM Code
Cancer
Buccal cavity and pharynx 140.00 to 149.00
Digestive system 150.00 to 159.00
Respirator system 160.00 to 165.00
Bones and joints 170.00
Soft tissue including heart 171.00
Skin 172.00 to 173.00
Breast 174.00 to 175.00
Kaposi’s sarcoma 176.00
Female genital system 179.00, 180.00 to 184.00
Male genital system 185.00 to 187.00
Urinary system 188.00 to 189.00
Eye and orbit 190.00
Brain and other nervous system 191.00 to 192.00
Endocrine system 164.00, 193.00 to 194.00
Ill-defined 195.00 to 196.00, 199.00, 202.00
Lymphoma 200.00 to 202.00, 202.10, 202.20, 202.80, 202.90
Multiple myeloma 203.00, 203.80
Leukemia 202.40, 203.10, 204.00 to 208.00
Benign neoplasms 210.00 to 229.00
Carcinoma in situ 230.00 to 234.00
Neoplasms of uncertain behavior 235.00 to 238.00
Neoplasms of unspecified nature 239.00
Stroke
Occlusion and stenosis of basilar artery 433.01, 433.10, 433.11, 433.21, 433.31, 433.81, 433.91
Cerebral thrombosis with/without cerebral infarction 434.00, 434.01, 434.11, 434.91
Acute, but ill-defined, cerebrovascular 436.00
Subarachnoid hemorrhage 430.00
Intracerebral hemorrhage 431.00
Asthma
Extrinsic asthma 493.00, 493.01, 493.02
Intrinsic asthma 493.10, 493.11, 493.12
Chronic obstructive asthma 493.20, 493.21, 493.22
Other forms of asthma 493.81, 493.82
Asthma unspecified 493.90, 493.91, 493.92
Liver disease
Acute and subacute necrosis of liver 570.0
Chronic liver disease and cirrhosis 571.0, 571.1, 571.2, 571.3, 571.4, 571.5, 571.6, 571.8, 571.9
Liver abscess 572.0. 572.1, 572.2, 572.3, 572.4, 572.8
Other disorders of liver 573.0, 573.1, 573.2, 573.3, 573.4, 573.5, 573.6, 573.8, 573.9
Arthritis
Psoriatic arthritis 696.0
Diffuse disease of connective tissue 710.0. 710.1. 710.2. 710.3, 710.4, 710.5, 710.8, 710.9
Infectious arthropathies 711.0, 711.1, 711.2, 711.3, 711.4, 711.5, 711.6, 711.7, 711.8, 711.9
Crystal arthropathies 712.1, 712.2, 712.3, 712.8, 712.9
Rheumatoid arthritis 714.0. 714.2, 714.3, 714.4, 714.8, 714.9
Osteoarthritis and allied disorders 715.0, 715.1, 715.2 715.3, 715.8, 715.9
Other/unspecified arthropathies 716.0, 716.1, 716.2, 716.3, 716.5, 716.6, 716.8, 716.9
Obesity
Obesity 278.00
Morbid obesity 278.01
Overweight 278.02
Obesity hypoventilation syndrome 278.03
Spinal disease
Spondylosis 721.0
Intervertebral disc disorder 722.0
Other cervical disorders 723.0
Low back pain 724.0

Top

Error processing SSI file

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions.